摘要
目的探讨Fascin蛋白的表达与早期非小细胞肺癌（NSCLC）患者术后预后的相关性。方法采用免疫组化方法，检测111例早期NSCLC组织中Fascin蛋白的表达情况。分析Fascin蛋白的表达水平与早期NSCLC患者临床病理特征及预后的关系。结果Fascin蛋白在早期NSCLC组织中表达阳性率为64．8％，癌旁组织中不表达。鳞癌阳性率为78．7％，显著高于腺癌阳性率48．0％（P〈0．01）。无论鳞癌组还是腺癌组，Fascin蛋白高表达与肿瘤的分期，淋巴结转移和患者预后显著相关（P〈0．05）。而且Fascin蛋白高表达是早期NSCLC患者预后的独立危险因素。结论Fascin蛋白有望成为早期NSCLC患者的预后生物标记物。
Objective To investigate the expression of Fascin in early-stage NSCLC, evaluate the relevance between Fascin expression level and prognosis. Methods The immunohistochemistry method was used to assess the expression of Fascin in 111 lung cancer FFPE tissues with stage I and lI NSCLC. The relationship between Fascin expression and the clinicopathological characteristics was analyzed. The prognostic significance of Fascin expression was evaluated with Kaplan-Meier survival analysis. Results In the early-stage of NSCLC, the positive rate of Fascin expression was 64.8%, no expression in the paracarcinoma tissue. The positive rate of squamous cell carcinoma was 78.7% and was significantly higher than that in adenocarcinoma 48.0% （P〈0.01）. Whether in squamous cell carcinoma or adenocarcinoma group, the expression of Fascin was correlated significantly with lymph node metastasis tumor stages and DFS（P〈0.05）. And the positive expression of Fascin was an independent risk factor of poor prognosis for patient with NSCLC. Conclusion Fascin is expected to be a biomarker for the prognosis of patients with early-stage NSCLC.
出处
《结核病与胸部肿瘤》
2017年第3期163-167,共5页
Tuberculosis and Thoracic Tumor
基金
北京市教育委员会科技计划面上项目（KM201410025025）
